Thromboprophylaxis in Pelvic and Acetabular Fractures: A Survey of Orthopaedic Surgeons
A survey of orthopaedic surgeons reveals that while thromboprophylaxis is widely used for pelvic and acetabular fractures, practices regarding agent selection, timing, and duration remain highly variable and lack consensus, with a notable gap between clinical habits and evidence-based guidelines.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a person suffers a severe break to the pelvis or the hip socket, the body enters a state of high alert. The trauma, the immobility that follows, and the necessary surgeries create a perfect storm for blood clots to form in the deep veins of the legs. These clots, known as venous thromboembolism, are dangerous because they can break loose and travel to the lungs, causing a life-threatening blockage. For decades, doctors have known that preventing these clots is a standard part of care, but they have lacked a single, universally agreed-upon rulebook for how to do it. Should the medicine be a daily injection or a simple pill? When should it start, and how long should it last? Without clear guidelines, the choice often falls to the individual surgeon, leading to a patchwork of different approaches depending on where the patient is treated.
A team of researchers set out to map this landscape by asking orthopaedic surgeons around the world how they actually handle these cases. They sent a detailed questionnaire to specialists who treat pelvic and hip socket fractures, asking them to describe their specific habits for preventing blood clots before surgery, after surgery, and for patients who do not undergo an operation. The goal was not to test a new drug or prove a new theory, but simply to understand the current reality of medical practice and see if there was any agreement among experts.
The survey reached 234 surgeons, and 56 of them responded, with 54 meeting the strict criteria for inclusion. Most of these respondents worked at major academic trauma centers in the United States and Canada, representing a high level of expertise in the field. The results revealed a picture of widespread care but deep inconsistency. Almost every surgeon reported using some form of medication to prevent clots before an operation, yet the choices varied significantly. The most common approach was to start a low-molecular-weight heparin injection immediately upon the patient's arrival at the hospital. This type of medication, which is given under the skin, was the preferred choice for nearly four out of five surgeons during the preoperative phase. No surgeon reported using a newer class of drugs called direct oral anticoagulants before surgery, despite some emerging research that suggests they might be effective.
Once the patient leaves the hospital, the strategy shifts dramatically for many. While injections remained common inside the hospital, the most frequent choice for treatment after discharge was a simple aspirin tablet. Nearly two-thirds of the surgeons switched to aspirin once the patient went home, likely because it is easy to take, inexpensive, and does not require needles. In contrast, the newer direct oral anticoagulants were almost entirely absent from post-discharge plans, used by fewer than one in twenty surgeons. This gap is notable because recent studies have suggested these newer drugs are safe and effective, yet they have not been adopted into routine practice. The duration of treatment was equally divided, with surgeons split between recommending protection for thirty days or for six weeks, and no single timeframe gaining the support of a majority.
The survey also looked at patients who do not require surgery. Here, the variation continued, with aspirin being the most common choice, followed by the injectable heparin. Again, the newer oral medications were rarely used. The researchers also asked about mechanical methods, such as devices that squeeze the legs to keep blood moving. While many surgeons used these devices alongside medication, nearly one-third did not use them at all, suggesting a lack of standardization even in non-drug therapies. Another area of uncertainty involved the use of filters placed in the large vein that carries blood from the legs to the heart. When a patient was found to have a clot before surgery, surgeons were evenly split on whether to place a filter to catch any future clots, indicating that even experienced experts disagree on the best course of action in these complex cases.
The study concluded that while the medical community is united in the belief that blood clots must be prevented, there is no consensus on how to do it best. The choices made by surgeons appear to be driven more by convenience and familiarity than by a unified body of evidence. The near-total absence of the newer oral anticoagulants in practice, despite evidence supporting their use, suggests a disconnect between what research has discovered and what happens in the hospital. The authors emphasize that without clear, evidence-based guidelines, this variation in care will likely continue. They call for future large-scale studies to compare these different approaches directly, hoping to eventually provide a single, reliable path forward for every patient facing this type of severe injury.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.